Dublin, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Biosimilars Market 2016-2020" report to their offering.

Biosimilars are defined as the follow-on versions of original biological medicines. These are separately developed after the patent protecting the original product has expired. Biosimilars are intended to have the same MOA as original biological drugs and are designed to treat the same diseases as the innovator's product. They have many similarities, but are not identical to, the reference biopharmaceutical product.

This comprehensive report forecasts the global biosimilars market to grow at a CAGR of 55.52% during the period 2016-2020.

The report states that the reluctant nature of physicians to prescribe biosimilars will be a challenge for the market. Physicians are reluctant to prescribe biosimilars to patients, as biologics cannot be substituted with these drugs. Biologics are developed using a living system or a genetically modified organism.

A slight variation in the manufacturing process, in terms of conditions and the formulation of biosimilar products can affect the safety and efficacy of the final product. Biosimilars can also not be used during post-marketing surveillance as the substitution of drugs is prohibited in a country during this period. Also, similar to generic drugs, physicians do not receive financial incentives for prescribing biosimilars.

Questions Answered:

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Companies Mentioned Include:

• Sandoz
• Hospira
• Teva Pharmaceuticals
• STADA
• Biocon
• Celltrion
• Dr Reddy's
• 3SBio
• Amgen
• Apotex
• Aspen
• Coherus Biosciences
• Daiichi Sankyo
• Emcure Pharmaceuticals
• Gedeon Richter
• GeneScience Pharmaceuticals
• GSK
• Hetero Drugs
• iBio
• Samsung Biologics
• Sanofi
• Synthon
• Wockhardt
  

Report Structure:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Pipeline portfolio

PART 06: Market landscape

PART 07: Market segmentation by application

PART 08: Market segmentation by end-user

PART 09: Geographical segmentation

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

PART 16: Appendix

PART 17: About the Author

For more information about this report visit http://www.researchandmarkets.com/research/xvszv2/global

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.